SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

STAMFORD, Conn., May 30, 2023 -- SpringWorks Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and... | May 30, 2023

Related Keywords

Saqib Islam ,Samantha Hilson Sandler ,National Cancer Institute ,Dana Farber Cancer Institute ,Fred Hutchinson Cancer Research Center ,Nasdaq ,Drug Administration ,European Commission ,Springworks Therapeutics Inc ,Works Therapeutics ,Chief Executive Officer ,Response Evaluation Criteria ,Solid Tumors ,New Drug Application ,Time Oncology Review ,Priority Review ,Prescription Drug User Fee Act ,Fast Track ,Breakthrough Therapy Designations ,Orphan Drug Designation ,Private Securities Litigation Reform Act ,Springwork Quarterly Report ,Investor Relations ,Hilson Sandler ,Cancer Statistics ,Springworks Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Bay ,023 ,Springworks ,Iopharmaceutical ,Company ,Ocused ,N ,Developing ,Medicines ,Or ,Patients ,Ith ,Evere ,Mare ,Iseases Swtx Us85205l1070 ,